Abstract:Expression of programmed death ligand 1 (PD-L1) is rendered a possible biomarker for immunotherapy targeting programmed death protein 1 (PD1) and PD-L1. Durable clinical responses have been demonstrated in patients with squamous cell carcinoma (SqCC) of the lung. Tumor infiltrating lymphocytes (TILs) are also regarded important players in immunomodulating therapies. Still, there is much uncertainty regarding the expression of the markers and associated tumor characteristics. We aimed to assess the prognostic impact and heterogeneity of PD-L1 expression across two antibodies, in conjunction with TILs, in SqCC of the lung. PD-L1 expression was investigated on a tissue microarray (TMA) of pulmonary SqCC using immunohistochemistry and two different clones (SP142, E1L3N). The cohort comprised all consecutive patients with primary resected pulmonary SqCC, without previous SqCC of other sites, diagnosed 2000-2013 at the Institute of Pathology, University of Bern. Epithelial expression of PD-L1 in primary tumors (n=372) and mediastinal lymph node (LN) metastases (n=27) was evaluated across 8 TMA cores per tumor using the following increment intervals: 0%; 1%; 5%; 10%; 20%; 30%, 50%. Intratumoral and intraepithelial infitrates of CD8+ T lymphocytes were determined. Results were compared with clinic-pathologic parameters including tumor related survival. The staining results correlated significantly between the two antibodies (r=0.822; p<0.001) with the best congruence for tumors with ≤1% or ≥30% positivity. These tumors had also very homogenous staining results across all TMA cores, indicating low levels of intratumoral heterogeneity, in contrast to tumors with 1-30% PD-L1 positivity (p<0.001 both antibodies). Stainings correlated significantly between primary tumors and LN metastases (p<0.001 both antibodies). High PD-L1 expression correlated with intratumoral and intraepithelial CD8+ lymphocyte counts in primaries (p<0.001 both antibodies). PD-L1 expression was not significantly associated with pT or pN staging. High PD-L1 expression was associated with shorter tumor related survival. Cut-offs with the best prognostic discrimination were 30% positivity for SP142 and 50% for E1LN3 in univariate analysis (p=0.001/p=0.008). PD-L1 expression, pT category and age of the patients, but not CD8+ TILs were independent prognostic factors in multivariate analysis (HR=2.265, p=0.013 for SP142; HR=2.323, p=0.014 for E1LN3). PD-L1 expression was an independent predictor of shorter tumor related survival in pulmonary SqCC across all stages. The homogeneity of PD-L1 expression in "no" or "high" staining tumors across different cores and primary versus LN metastases indicates a valid assessment on small tissue samples and LN-metastases.

Chaperone-Mediated Autophagy Markers LAMP2A and HSC70 Are Independent Adverse Prognostic Markers in Primary Resected Squamous Cell Carcinomas of the Lung.

LAMP1 Expression is Associated with Malignant Behaviours and Predicts Unfavourable Prognosis in Laryngeal Squamous Cell Carcinoma.

Chaperone-Mediated Autophagy Markers LAMP2A and HSPA8 in Advanced Non-Small Cell Lung Cancer after Neoadjuvant Therapy

The Prognostic Significance of pSTAT1 and CD163 Expressions in Surgically Resected Stage 1 Pulmonary Squamous Cell Carcinomas

Proteomic and Phosphoproteomic Maps of Lung Squamous Cell Carcinoma from Chinese Patients.

Expression Analysis of Autophagy Related Markers LC3B, P62 and HMGB1 Indicate an Autophagy-Independent Negative Prognostic Impact of High P62 Expression in Pulmonary Squamous Cell Carcinomas

Prognostic Value of the Autophagy Markers LC3 and P62/sqstm1 in Early-Stage Non-Small Cell Lung Cancer.

The combined immunohistochemical expression of AMBRA1 and SQSTM1 identifies patients with poorly differentiated cutaneous squamous cell carcinoma at risk of metastasis: A proof of concept study

Elevated Serum LAMC2 is Associated with Lymph Node Metastasis and Predicts Poor Prognosis in Penile Squamous Cell Carcinoma.

Chaperone-mediated autophagy receptor modulates tumor growth and chemoresistance in non-small cell lung cancer

Prognostic Gene Signature for Squamous Cell Carcinoma with a Higher Risk for Treatment Failure and Accelerated MEK-ERK Pathway Activity

P-127 * SHOTGUN AND TARGETED PROTEOMICS REVEAL THAT PRE-SURGERY SERUM LEVELS OF LRG1, SAA, AND C4BP MAY REFINE PROGNOSIS OF RESECTED SQUAMOUS CELL LUNG CANCER

Loss of LIMCH1 Predicts Poor Prognosis in Patients with Surgically Resected Lung Adenocarcinoma: A Study Based on Immunohistochemical Analysis and Bioinformatics

PD-L1 Expression by Two Complementary Diagnostic Assays and Mrna in Situ Hybridization in Small Cell Lung Cancer.

High Expression of Octamer-Binding Transcription Factor 4a, Prominin-1 and Aldehyde Dehydrogenase Strongly Indicates Involvement in the Initiation of Lung Adenocarcinoma Resulting in Shorter Disease-Free Intervals

Identification of HEPACAM2 as a novel and specific marker of small cell carcinoma

Intratumoral Abundance of M2-Macrophages is Associated With Unfavorable Prognosis and Markers of T-Cell Exhaustion in Small Cell Lung Cancer Patients

P2.01-052 High PD-L1 Expression is Associated with Worse Prognosis in Primary Resected Squamous Cell Carcinomas of the Lung

LAMP2 as a Biomarker Related to Prognosis and Immune Infiltration in Esophageal Cancer and Other Cancers: A Comprehensive Pan-Cancer Analysis

LAMC2 as a prognostic biomarker in human cancer: a systematic review and meta-analysis

Lysosome-Associated Membrane Protein-3 (LAMP3) Expression in Oral Squamous Cell Carcinoma and Its Relationship With Clinicopathological Parameters: A Cross-Sectional Study